Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients

  • Luciana Brosina de Leon Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brasil
  • Cristiane Valle Tovo Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brasil
  • Dimas Alexandre Kliemann Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brasil
  • Angelo Alves de Mattos Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brasil
  • Alberi Adolfo Feltrin Hospital Nossa Senhora da Conceição, Porto Alegre, Brasil
  • Liliane Souto Pacheco Hospital Nossa Senhora da Conceição, Porto Alegre, Brasil
  • Paulo Roberto Lerias de Almeida Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brasil
Keywords: HIV, HCV, peginterferon, HAART, therapy

Abstract

Introduction: Many patients coinfected with the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are using highly active antiretroviral therapy (HAART) and HCV therapy with peginterferon (PEG-IFN) and ribavirina (RBV) because the use of direct-acting antivirals is not a reality in some countries. To know the impact of such medications in the sustained virological response (SVR) during HCV treatment is of great importance.

Methodology: This was a retrospective cohort study of 215 coinfected HIV/HCV patients. The patients were treated with PEG-IFN and RBV between 2007 and 2013 and analyzed by intention to treat. Treatment-experienced patients to HCV and carriers of hepatitis B were excluded. Demographic data (gender, age), mode of infection, HCV genotype, HCV viral load, hepatic fibrosis, HIV status, and type of PEG were evaluated. One hundred eighty-eight (87.4%) patients were using HAART.

Results: SVR was achieved in 55 (29.3%) patients using HAART and in 9 (33.3%) patients not using HAART (p = 0.86). There was no difference in SVR between different HAART medications and regimens using two reverse transcriptase inhibitor nucleosides (NRTIs) or the use of protease inhibitors and non-NRTIs (27.1% versus 31.5%; p = 0.61). The predictive factors for obtaining SVR were low HCV viral load, non-1 genotype, and the use of peginterferon-α2a.

Conclusions: The use of HAART does not influence the SVR of HCV under PEG-IFN and RBV therapy in HIV/HCV coinfected patients.

Published
2016-08-02
How to Cite
1.
de Leon LB, Tovo CV, Kliemann DA, de Mattos AA, Feltrin AA, Pacheco LS, de Almeida PRL (2016) Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients. J Infect Dev Ctries 10:762-769. doi: 10.3855/jidc.7542
Section
Original Articles